Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Gliosarcoma 43Glioblastoma 43Brain Neoplasms 29Glioma 23Sarcoma 20Astrocytoma 13Oligodendroglioma 10Central Nervous System Neoplasms 8Colorectal Neoplasms 7Neoplasm Metastasis 6Recurrence 5Stomach Neoplasms 4Neoplasms 4Hemangiosarcoma 4Carcinoma, Hepatocellular 4Sarcoma, Kaposi 3Ovarian Neoplasms 3Osteosarcoma 3Gastrointestinal Stromal Tumors 3Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leiomyosarcoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Diffuse Intrinsic Pontine Glioma 2

Interventions

temsirolimus 1linrodostat 1ixabepilone 1Taxes 1Sunitinib 1Sirolimus 1Paclitaxel 1Nivolumab 1Laparoscopy 1Immunoglobulin G 1Epothilones 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Adenocarcinoma × Bevacizumab × Sarcoma × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡